Cargando…
Long-term follow up of Hodgkin lymphoma
BACKGROUND: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overall survival (OS) of patients with HL and compared their survival between decades and with the expected survival of a general population. RESULTS: The median follow-up was 22 years. The median OS was 33...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837753/ https://www.ncbi.nlm.nih.gov/pubmed/29545926 http://dx.doi.org/10.18632/oncotarget.24392 |
_version_ | 1783304141958807552 |
---|---|
author | Perez-Callejo, David Zurutuza, Lorea Royuela, Ana Torrente, Maria Núñez, Beatriz Calvo, Virginia Méndez, Miriam Franco, Fernando Brenes, María Auxiliadora Sánchez, Juan Cristobal Provencio, Mariano |
author_facet | Perez-Callejo, David Zurutuza, Lorea Royuela, Ana Torrente, Maria Núñez, Beatriz Calvo, Virginia Méndez, Miriam Franco, Fernando Brenes, María Auxiliadora Sánchez, Juan Cristobal Provencio, Mariano |
author_sort | Perez-Callejo, David |
collection | PubMed |
description | BACKGROUND: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overall survival (OS) of patients with HL and compared their survival between decades and with the expected survival of a general population. RESULTS: The median follow-up was 22 years. The median OS was 33 years. The incidence mortality rate for all causes is 2 per every 100 patients per year. The OS of our cohort at 10 years from diagnosis was 76% (95% CI: 72–79) and 52% at 30 years (95% CI: 48–57). Overall SMR (1980–2013) was 2,943 (95% CI: 2,518–3,439). Excluding the primary tumor as the cause of death, the SMR obtained is 2,266 (95% CI: 1,895–2,710). The SMR for those patients diagnosed before the year 2000 was 2,097 (95% CI: 1,732–2,539); and for those diagnosed after 2000 was 5,218 (95% CI: 8,655). The group of patients diagnosed after 2000 had statistically significant more advanced stages, were older and less responsive to treatment. CONCLUSIONS: Despite the advances achieved, the risk of death remains higher than in the general population, mainly for those patients diagnosed after year 2000, even after almost 40 years of follow-up. This data might suggest a shift to more aggressive forms of disease in recent years. PATIENTS AND METHODS: A total of 595 patients diagnosed with HL were included between January 1966 and February 2014. The standardized mortality ratio (SMR) was analyzed using the annual rate of mortality in the general Spanish population, adjusted for age, sex and time period. |
format | Online Article Text |
id | pubmed-5837753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-58377532018-03-15 Long-term follow up of Hodgkin lymphoma Perez-Callejo, David Zurutuza, Lorea Royuela, Ana Torrente, Maria Núñez, Beatriz Calvo, Virginia Méndez, Miriam Franco, Fernando Brenes, María Auxiliadora Sánchez, Juan Cristobal Provencio, Mariano Oncotarget Research Paper BACKGROUND: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overall survival (OS) of patients with HL and compared their survival between decades and with the expected survival of a general population. RESULTS: The median follow-up was 22 years. The median OS was 33 years. The incidence mortality rate for all causes is 2 per every 100 patients per year. The OS of our cohort at 10 years from diagnosis was 76% (95% CI: 72–79) and 52% at 30 years (95% CI: 48–57). Overall SMR (1980–2013) was 2,943 (95% CI: 2,518–3,439). Excluding the primary tumor as the cause of death, the SMR obtained is 2,266 (95% CI: 1,895–2,710). The SMR for those patients diagnosed before the year 2000 was 2,097 (95% CI: 1,732–2,539); and for those diagnosed after 2000 was 5,218 (95% CI: 8,655). The group of patients diagnosed after 2000 had statistically significant more advanced stages, were older and less responsive to treatment. CONCLUSIONS: Despite the advances achieved, the risk of death remains higher than in the general population, mainly for those patients diagnosed after year 2000, even after almost 40 years of follow-up. This data might suggest a shift to more aggressive forms of disease in recent years. PATIENTS AND METHODS: A total of 595 patients diagnosed with HL were included between January 1966 and February 2014. The standardized mortality ratio (SMR) was analyzed using the annual rate of mortality in the general Spanish population, adjusted for age, sex and time period. Impact Journals LLC 2018-02-03 /pmc/articles/PMC5837753/ /pubmed/29545926 http://dx.doi.org/10.18632/oncotarget.24392 Text en Copyright: © 2018 Perez-Callejo et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Perez-Callejo, David Zurutuza, Lorea Royuela, Ana Torrente, Maria Núñez, Beatriz Calvo, Virginia Méndez, Miriam Franco, Fernando Brenes, María Auxiliadora Sánchez, Juan Cristobal Provencio, Mariano Long-term follow up of Hodgkin lymphoma |
title | Long-term follow up of Hodgkin lymphoma |
title_full | Long-term follow up of Hodgkin lymphoma |
title_fullStr | Long-term follow up of Hodgkin lymphoma |
title_full_unstemmed | Long-term follow up of Hodgkin lymphoma |
title_short | Long-term follow up of Hodgkin lymphoma |
title_sort | long-term follow up of hodgkin lymphoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837753/ https://www.ncbi.nlm.nih.gov/pubmed/29545926 http://dx.doi.org/10.18632/oncotarget.24392 |
work_keys_str_mv | AT perezcallejodavid longtermfollowupofhodgkinlymphoma AT zurutuzalorea longtermfollowupofhodgkinlymphoma AT royuelaana longtermfollowupofhodgkinlymphoma AT torrentemaria longtermfollowupofhodgkinlymphoma AT nunezbeatriz longtermfollowupofhodgkinlymphoma AT calvovirginia longtermfollowupofhodgkinlymphoma AT mendezmiriam longtermfollowupofhodgkinlymphoma AT francofernando longtermfollowupofhodgkinlymphoma AT brenesmariaauxiliadora longtermfollowupofhodgkinlymphoma AT sanchezjuancristobal longtermfollowupofhodgkinlymphoma AT provenciomariano longtermfollowupofhodgkinlymphoma |